March 2012 Volume 8, Issue 3

Volume 8, Issue 3 | March 2012

March 2012

In this Issue

Feature

Drug Discovery News Placeholder Image

AACR Annual Meeting 2012: Concentrated delivery

In an age when diverse oncology areas must pull together and more therapeutic options emerge, AACR packs a lot into a few days
Drug Discovery News Placeholder Image

AACR Annual Meeting 2012: Photos and Other Additional Material

Additional pre-show coverage for AACR Annual Meeting 2012

Research & Development

Drug Discovery News Placeholder Image

Amgen takes a big BiTE

Company signs $1.16 billion merger agreement with oncology firm Micromet
Drug Discovery News Placeholder Image

Homing in on hematology

Celgene acquires Avila Therapeutics in definitive merger agreement
Drug Discovery News Placeholder Image

Cytomedix undergoes business regeneration

Company acquires Aldagen in stock deal valued at $40 million, becomes regenerative stem-cell therapy operation
Drug Discovery News Placeholder Image

Engendering the collaborative spirit to cure MS

Myelin Repair Foundation, ENDECE Neural explore small- molecule compounds’ potential to reverse symptoms of multiple sclerosis
Drug Discovery News Placeholder Image

Puff the magic drug-delivery system

Zogenix and Battelle to collaborate on development of DosePro subcutaneous delivery technology
Drug Discovery News Placeholder Image

IMUC, University of Pa. in deal for dendritic-cell production technology

ImmunoCellular Therapeutics (IMUC) announced in late February that it has entered into an agreement with the University of Pennsylvania under which the school has granted IMUC an exclusive, worldwide license for a patent-pending technology for the production of high-activity dendritic cells

Diagnostics

Drug Discovery News Placeholder Image

Playing hard to get

Illumina remains defiant in the wake of Roche’s takeover bid
Drug Discovery News Placeholder Image

Picking up a Chip

Signal Genetics acquires ChipDX, expands molecular diagnostics assets in oncology
Drug Discovery News Placeholder Image

Trovagene closes on CLIA

Company completes acquisition of MultiGEN Diagnostics’ clinical laboratory assets
Drug Discovery News Placeholder Image

New companions for new tests

Siemens heralds growth in CDx market with pair of partnerships
Drug Discovery News Placeholder Image

Scary dairy

GeneThera acquires Applied Genetics in effort that indirectly fights Crohn’s disease
Drug Discovery News Placeholder Image

A*STAR, GE Global Research in medical imaging deal

GE Global Research has signed a memorandum of understanding (MOU) with Singapore’s Agency of Science, Technology and Research, also known as A*STAR.

Global News

Drug Discovery News Placeholder Image

Oceania- bound and generic-focused

Watson Pharmaceuticals acquires Ascent Pharmahealth from Strides Arcolab for $393 million
Drug Discovery News Placeholder Image

A deal with first-in-class cancer potential

Merck KGaA and Threshold announce global agreement to co-develop and commercialize Phase III hypoxia-targeted drug TH-302
Drug Discovery News Placeholder Image

The power of partnering

Sistemic is latest company to sign on for TiGenix’s stem cell therapy consortium
Drug Discovery News Placeholder Image

A breath of fresh air

Almirall, BioFocus announce respiratory alliance
Drug Discovery News Placeholder Image

Two for C

BioLineRx in-licenses two oral hepatitis C treatments

Omics & Systems Biology

Drug Discovery News Placeholder Image

Sunshine State collaboration

Sanford-Burnham, Florida Hospital and Moffitt partner to develop PMP Florida
Drug Discovery News Placeholder Image

Genentech reaches for the stars

Company gains access to Constellation Pharmaceuticals’ epigenetics expertise with $95 million deal
Drug Discovery News Placeholder Image

Doing the monogenic mambo

Shire, Sangamo to develop therapies for hemophilia, other monogenic diseases
Drug Discovery News Placeholder Image

Spanish partners to develop low-cost informatics methods for clinical genomics

Venture attracts $1.3 million grant for ‘new frontier’ of data interpretation for clinical and diagnostic applications
Drug Discovery News Placeholder Image

IDT on deck

Integrated DNA Technologies acquires 1st BASE oligonucleotide business in Singapore

Commentary

Drug Discovery News Placeholder Image

Guest Commentary: So you want to collaborate?

By combining their ingenuity in a collaboration, industry and academia, for better or worse, become partners with both shared and diverse interests. As a result, the already complex inventorship matrix is made even more challenging. By combining their ingenuity in a collaboration, industry and academia, for better or worse, become partners with both shared and diverse interests. As a result, the already complex inventorship matrix is made even more challenging.
Drug Discovery News Placeholder Image

Out of Order: Watch that last step

Every year, the pharmaceutical and biotech industries spend billions on cutting-edge R&D, clinical trials, sales and marketing and medical education and training, to get just a handful of drugs into the medical community. And yet, every year, another drug is recalled or sees its market significantly curtailed by unfortunate events in that final step— delivery to patients.

Editor's Focus

Drug Discovery News Placeholder Image

Falling short of filling unmet medical needs

Shouldn’t addressing drug shortages be a top priority for an industry that claims—on every press release that crosses my desk and in most of the stories we write—that its very reason for existence is “to address a high unmet medical need?"

Government Watch

Drug Discovery News Placeholder Image

FDA provides guidance on biosimilars

The U.S. Food and Drug Administration (FDA) has issued three draft guidance documents on biosimilar product development to assist the industry in securing approval for such products in the United States.
Drug Discovery News Placeholder Image

Privacy vs. right to know

Presidential Commission on Bioethics debates genome sequencing
Drug Discovery News Placeholder Image

OK as-is?

Conflict-of-interest rules for FDA not needed, says agency commissioner
Drug Discovery News Placeholder Image

SPRINTing to a cure

Congressional lawmakers acknowledge need to invest in U.S. research

Special Reports

Drug Discovery News Placeholder Image

Just a shot in the dark?

Cancer vaccines slow to catch on

Tools & Technology

Drug Discovery News Placeholder Image

Addtech adds one

Addtech Life Science closes acquisition of BioNordika
Drug Discovery News Placeholder Image

Speaking the right language

Linguamatics, Brandwatch and University Of Sussex announce project to enhance language processing of ‘big data’
Drug Discovery News Placeholder Image

A hot microplate

Scripps Research, Brooks Life Science Systems partner on microplate imaging system
Drug Discovery News Placeholder Image

Building on their relationship

Vela Laboratories and Anagnostics enter strategic partnership to offer hybcell technology to biotech and pharma customers under GMP conditions
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue